Posted by Michael Wonder on 15 Sep 2021
Pulmocide’s lead drug candidate opelconazole (PC945) granted orphan drug, fast track and qualified infectious disease product designations by US FDA
15 September 2021 - Pulmocide today announced that the US FDA has granted orphan drug, fast track and qualified infectious disease product designations for opelconazole (PC945) for the treatment of invasive pulmonary aspergillosis.
Pulmocide’s lead product is opelconazole (PC945), a novel anti-fungal therapy specifically designed for inhaled use to maximise the amount of drug in the lung and spare systemic exposure.
